Nanobiotechnology integrates the principles of nanotechnology with biotechnology, focusing on innovative solutions for health and agriculture. Companies in this sector create nanoparticles for drug delivery, diagnostics, and therapeutics. The industry is rapidly evolving, with increasing demand for more effective treatment options and advanced medical technologies. Key trends include personalized medicine and smart drug delivery systems. This convergence of fields is paving the way toward innovative medical therapies, shaping a future where precision meets healthcare. Following recent advancements in RNA technologies, the industry is gaining momentum, especially for vaccine development and treatment for chronic diseases.


This list features 28 prominent nanobiotechnology companies, varying in size from startups with under ten employees to those with over 200. Headquartered across multiple countries including Canada, Germany, Brazil, and the United States, these firms were founded between 2002 and 2022. Their expertise ranges from lipid nanoparticle formulations for mRNA vaccines to advanced drug delivery systems. Significant collaboration is evident among companies like Acuitas Therapeutics, known for its mRNA delivery research, and innovative firms like Genevant Sciences, which focuses on nucleic acid delivery systems.


Top 28 Nanobiotechnology Companies


1. Precision NanoSystems is now part of Cytiva


Precision NanoSystems, now part of Cytiva, is a biotechnology firm based in Vancouver, British Columbia, Canada. Founded in 2010, the company specializes in lipid nanoparticle technologies that are crucial for the development of genomic medicines, including mRNA vaccines and therapeutics. They offer a range of services from formulation development to cGMP manufacturing, primarily targeting biopharmaceutical companies engaged in drug development for various diseases. Their innovative NanoAssemblr technology facilitates the efficient production of lipid nanoparticles, which are essential for delivering nucleic acid-based therapies. Precision NanoSystems has played a significant role in advancing the field of genomic medicine, particularly in the wake of the COVID-19 pandemic, where mRNA vaccines have gained prominence. Their expertise in lipid nanoparticle formulation and manufacturing positions them as a key player in the nanobiotechnology sector.


2. Apurano Pharmaceuticals GmbH


Apurano Pharmaceuticals GmbH, founded in 2014 and based in Warngau, Bavaria, Germany, is a private pharmaceutical and biotechnology company. The firm specializes in smart bio-nanotechnology, focusing on the development of innovative nanotechnology products designed to enhance drug delivery systems and improve therapeutic efficacy. With a team of 24 employees, Apurano is dedicated to advancing healthcare solutions for providers and researchers alike. Their product pipeline reflects a commitment to addressing various medical indications through cutting-edge nanotechnology applications. Although the company has not reported any funding, its ongoing operations and specialized focus position it as a relevant entity within the nanobiotechnology industry.


3. nanoComposix | Fortis Life Sciences

  • Website: nanocomposix.com
  • Ownership type: Private Equity
  • Headquarters: San Diego, California, United States (USA)
  • Employee distribution: United States (USA) 100%
  • Latest funding: July 2021
  • Founded year: 2004
  • Headcount: 51-200
  • LinkedIn: nanocomposix

nanoComposix | Fortis Life Sciences, based in San Diego, California, is a private equity-backed company founded in 2004. The firm specializes in the production and customization of nanoparticles, catering to the biotechnology and pharmaceutical sectors. Their product range includes gold, silver, silica, magnetic, and aluminum nanoparticles, among others, which are utilized in diagnostics and nanomedicine applications. The company provides contract research and development services, as well as contract manufacturing, ensuring that clients receive tailored solutions to meet their specific needs. With a strong emphasis on quality, nanoComposix is ISO 13485:2016 certified, which underscores their commitment to maintaining high standards in the production of medical materials. Their operations are supported by a multidisciplinary team of scientists, enabling them to offer custom nanoparticle formulations with precise optical and physical properties. This capability is essential for applications ranging from medical devices to drug delivery systems, highlighting their integral role in advancing nanobiotechnology.


4. Nanovex Biotechnologies


Nanovex Biotechnologies is a private biotechnology company founded in 2014, based in Honduras, with a workforce of approximately 23 employees. The company specializes in drug delivery systems and nanotechnology solutions, focusing on enhancing the efficacy and safety of pharmaceuticals through innovative delivery mechanisms. Their product offerings include liposomes and synthetic exosomes, which are utilized in both the pharmaceutical and cosmetic industries. Nanovex is dedicated to improving research and development productivity by providing customizable solutions to complex delivery problems. They have also received funding, amounting to €81,868 in a grant in 2019, which supports their ongoing projects and innovations in the field. The company operates primarily in Spain, indicating a strategic focus on European markets.


5. Genevant Sciences

  • Website: genevant.com
  • Ownership type: Private
  • Headquarters: Vancouver, British Columbia, Canada
  • Employee distribution: Canada 96%, United States (USA) 4%
  • Founded year: 2018
  • Headcount: 11-50
  • LinkedIn: genevant

Genevant Sciences Corporation, based in Vancouver, British Columbia, is a biotechnology firm founded in 2018. The company focuses on developing advanced nucleic acid delivery systems, particularly utilizing lipid nanoparticles (LNPs). Genevant's technology is crucial for the effective delivery of mRNA and siRNA therapies, addressing significant challenges in the field of drug development. With a robust patent estate of over 700 patents, Genevant has established itself as a key player in the nucleic acid delivery space. The company collaborates with various pharmaceutical and biotechnology firms to enhance the development of innovative therapies. Their platforms have been validated through numerous clinical programs, showcasing their commitment to transforming patient care through improved drug delivery solutions.


6. NanoScoping - Nanotechnology


NanoScoping - Nanotechnology, founded in 2014 and based in Florianopolis, Brazil, is a private company that specializes in the application of nanotechnology to develop sustainable and high-performance products. With a workforce of 22 employees, the company focuses on creating innovative solutions for agriculture, nutrition, cosmetics, and veterinary medicine. Their product lines include nanoencapsulated ingredients designed to enhance efficacy and absorption, catering to both businesses and consumers seeking eco-friendly options. NanoScoping has been recognized for its commitment to sustainability, having won awards such as the Prêmio Nacional de Inovação. The company emphasizes the use of natural ingredients and green technologies, ensuring that their processes are environmentally responsible. Their research and development efforts are geared towards creating effective, safe, and sustainable products that meet the needs of various industries.


7. Acuitas Therapeutics

  • Website: acuitastx.com
  • Ownership type: Private
  • Headquarters: Vancouver, British Columbia, Canada
  • Employee distribution: Canada 100%
  • Founded year: 2009
  • Headcount: 51-200
  • LinkedIn: acuitastx

Acuitas Therapeutics, founded in 2009 and based in Vancouver, British Columbia, is a biotechnology company that specializes in the development of lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics. The company collaborates with pharmaceutical and biotechnology firms, as well as academic institutions, to advance innovative therapies aimed at addressing unmet clinical needs. Acuitas is recognized for its clinically validated LNP technology, which has been instrumental in the development of RNAi therapeutics, including Onpattro™, the first drug of its kind to receive regulatory approval. Additionally, Acuitas has played a significant role in the development of the mRNA COVID-19 vaccine, COMIRNATY®, in partnership with BioNTech and Pfizer. Their ongoing work includes developing vaccines for other infectious diseases and exploring mRNA-LNP immunomodulation therapies for cancer treatment.


8. Magtech Brasil

  • Website: magtechbrasil.com.br
  • Ownership type: Private
  • Headquarters: Rio De Janeiro, Rio De Janeiro, Brazil
  • Employee distribution: Brazil 100%
  • Founded year: 2017
  • Headcount: 1-10
  • LinkedIn: magtechbrasil

Magtech Brasil, founded in 2017 and based in Rio de Janeiro, is a private biotechnology firm focused on the development of multifunctional nanoparticles aimed at health solutions. The company operates primarily in the biotechnology and life sciences sectors, providing a range of research and development services. These services include project design, reverse engineering, and biological validations, which are essential for advancing nanobiotechnology applications. Magtech's product portfolio features innovative offerings such as magnetic nanoparticles, quantum dots, and synthetic fluorophores, which are utilized in various scientific research applications. The company prides itself on its collaborative approach, working closely with academic institutions to foster innovation and support scientific entrepreneurship. With a small but dedicated team, Magtech is positioned to contribute significantly to the evolving field of nanobiotechnology.


9. Ceres Nanosciences, Inc.

  • Website: ceresnano.com
  • Ownership type: Private Equity
  • Headquarters: Manassas, Virginia, United States (USA)
  • Employee distribution: United States (USA) 100%
  • Latest funding: $5.0M, September 2022
  • Founded year: 2008
  • Headcount: 11-50
  • LinkedIn: ceres-nanosciences-inc.

Ceres Nanosciences, Inc., founded in 2008 and based in Manassas, Virginia, is a biotechnology company that focuses on developing diagnostic and research products. The company leverages its proprietary Nanotrap® particle technology to capture and concentrate low abundance analytes from biological samples. This technology enhances the ability of healthcare providers and research institutions to detect diseases more accurately and at earlier stages. Ceres has developed a range of products, including the NEAT Liquid Biopsy Kit and various Nanotrap particles tailored for specific applications. Their commitment to innovation is underscored by their collaborations with notable organizations, including the National Institutes of Health and the Bill and Melinda Gates Foundation. In September 2022, Ceres secured $5 million in funding, reflecting investor confidence in their technology and its potential impact on the healthcare sector.


10. ANP Technologies, Inc.

  • Website: anptinc.com
  • Ownership type: Private
  • Headquarters: United States (USA)
  • Employee distribution: United States (USA) 100%
  • Founded year: 2002
  • Headcount: 11-50
  • LinkedIn: anp-technologies-inc.

ANP Technologies, Inc. is a biotechnology firm based in Newark, Delaware, established in 2002. The company focuses on creating innovative nano-therapeutics and drug delivery systems, catering primarily to pharmaceutical companies and research institutions. Their product offerings include advanced solutions for immunogenicity testing and biodefense applications. ANP has developed a range of therapies, including nanoencapsulated chemotherapeutics and antibody therapies, and is actively involved in the research and development of immune-oncology and mRNA-based vaccines. Notably, they have partnered with Fulgent Pharma and Moffitt Cancer Center to advance targeted therapies for leukemia, showcasing their collaborative approach to tackling complex medical challenges. ANP Technologies has also received FDA approval to initiate Phase I clinical trials for their nanoencapsulated paclitaxel, indicating their commitment to bringing innovative treatments to market. Their ISO 9001:2008 certification reflects a dedication to quality management in their operations, further underscoring their professional standards in the biotechnology sector.


11. 1Globe Health Institute

  • Website: 1globe-usa.com
  • Ownership type: Private
  • Headquarters: Norwood, Massachusetts, United States (USA)
  • Employee distribution: United States (USA) 100%
  • Founded year: 2012
  • Headcount: 11-50
  • LinkedIn: 1globe-health-institute

1Globe Health Institute, based in Norwood, Massachusetts, is a biotechnology firm founded in 2012. The company specializes in cancer therapeutics and innovative medical technologies, focusing on the discovery and commercialization of targeted therapeutic agents. Their research is driven by proprietary technology platforms, including asymmetrical gene-silencing technology (aiRNA) and novel nanotechnology for drug delivery systems. 1Globe Health Institute aims to tackle hard-to-treat diseases by developing advanced therapeutic agents that can effectively target cancerous cells. The organization operates with a culture that blends academic rigor with entrepreneurial spirit, fostering an environment where scientific innovation thrives. Their team consists of experienced biological scientists and clinicians who are dedicated to accelerating the timeline for bringing new therapeutics to market. The company is strategically located near the Boston area, a hub for scientific and pharmaceutical research, which enhances their collaborative opportunities within the industry.


12. MagGenome


MagGenome Technologies Pvt. Ltd., founded in 2014 and based in Chennai, Tamil Nadu, India, is a private biotechnology firm that specializes in nano-biotechnology solutions. The company develops and manufactures products based on magnetic nanoparticles, primarily aimed at DNA and RNA extraction, purification, and sample collection. Their offerings include a range of kits for various biological samples, such as blood, saliva, and soil, which are essential for researchers and diagnostic laboratories in the life sciences and pharmaceutical sectors. MagGenome's innovative technologies are designed to improve molecular diagnostics and research capabilities, making them a significant player in the biotechnology field. The company operates entirely within India and has established a reputation for providing high-quality, efficient solutions for molecular biology applications.


13. etherna

  • Website: etherna.be
  • Ownership type: Venture Capital
  • Headquarters: Niel, Flanders, Belgium
  • Employee distribution: Belgium 100%
  • Latest funding: Series B, $38.9M, August 2022
  • Founded year: 2013
  • Headcount: 51-200
  • LinkedIn: etherna-engineering-rna

etherna, founded in 2013 and based in Niel, Belgium, is a biotechnology company that specializes in RNA therapeutics and manufacturing services. The company supports pharmaceutical and biotech firms in developing and producing nucleic acid-based therapeutics and vaccines. With a strong focus on innovative RNA technology, etherna collaborates with partners to enhance the efficacy and delivery of RNA products. Their proprietary platforms, particularly in customizable lipid nanoparticles (cLNPs) and mRNA chemistry, allow them to tackle complex challenges in the field. In August 2022, etherna secured €38.9 million in Series B funding, which underscores their growth and commitment to advancing RNA medicine. The company operates with a skilled team and state-of-the-art facilities, positioning itself as a key player in the RNA therapeutics landscape.


14. Liselo Labs

  • Website: liselo.com
  • Ownership type: Private
  • Headquarters: Hilton, Kwazulu-Natal, South Africa
  • Employee distribution: South Africa 81%, Lesotho 19%
  • Founded year: 2011
  • Headcount: 11-50
  • LinkedIn: liselo-labs

Liselo Labs, founded in 2011 and based in Hilton, Kwazulu-Natal, South Africa, is a private biotechnology firm dedicated to research and development in nanotechnology, biotechnology, and health sciences. With a team of molecular biologists, microbiologists, and nanotechnology engineers, Liselo Labs focuses on creating innovative solutions tailored to the unique challenges faced by healthcare providers and agricultural stakeholders in Africa. Their offerings include laboratory diagnostics, biologics, and health advisory services, with a notable emphasis on developing custom in vitro diagnostic (IVD) devices. The company has established a strong presence in multiple African countries, including Lesotho, Namibia, and Botswana, and has made significant contributions to COVID-19 testing and advisory services. Their biologics division is particularly noteworthy for its production of polyclonal antibodies and recombinant proteins, showcasing their application of nanotechnology in therapeutic development. Liselo Labs operates with a vision to harness African innovation and improve health outcomes through the integration of advanced technologies.


15. Affilogic

  • Website: affilogic.com
  • Ownership type: Private
  • Headquarters: Nantes, Pays De La Loire, France
  • Employee distribution: France 100%
  • Founded year: 2010
  • Headcount: 11-50
  • LinkedIn: affilogic

Affilogic, founded in 2010 and based in Nantes, France, is a biotechnology company that specializes in the development of Nanofitins. These are innovative therapeutic proteins designed for various medical applications, particularly in cancer treatment and the oral delivery of biologics. Affilogic collaborates with pharmaceutical companies and research institutions to enhance drug development and delivery methods. Their technology platforms focus on critical areas such as half-life extension, blood-brain barrier crossing, and oral-to-systemic delivery. The company has been involved in several significant projects, including the development of multispecific Nanofitins aimed at modulating tumor microenvironments and enhancing immune responses against cancer. Affilogic's research efforts also extend to addressing global health challenges, such as developing Nanofitins for respiratory infections, supported by funding from the Bill & Melinda Gates Foundation. Their commitment to innovation and collaboration positions them as a relevant entity in the biotechnology sector.


16. Peel Therapeutics

  • Website: peeltx.com
  • Ownership type: Venture Capital
  • Headquarters: Salt Lake City, Utah, United States (USA)
  • Employee distribution: Israel 50%, United States (USA) 50%
  • Latest funding: Series A, February 2025
  • Founded year: 2015
  • Headcount: 11-50
  • LinkedIn: peel-therapeutics

Peel Therapeutics, founded in 2015 and based in Salt Lake City, Utah, is a biotechnology firm that specializes in creating innovative therapies inspired by evolutionary biology. The company is focused on addressing significant unmet clinical needs in oncology and immune diseases. Their product pipeline includes PEEL-224, a PEGylated TOP1 inhibitor, and EP53 Lipid Nanoparticles, which leverage the tumor suppressor gene from elephants to combat cancer. Peel Therapeutics employs a unique approach that combines insights from nature with advanced drug delivery technologies, aiming to improve patient outcomes. The company operates with a team of experts in both the United States and Israel, reflecting a blend of scientific and medical expertise. Their commitment to research and development is evident in their clinical trials and ongoing studies, which seek to validate the efficacy of their novel therapies.


17. ACM Biolabs

  • Website: acmbiolabs.com
  • Ownership type: Venture Capital
  • Headquarters: Singapore
  • Employee distribution: Singapore 100%
  • Latest funding: $6.8M, September 2022
  • Founded year: 2013
  • Headcount: 11-50
  • LinkedIn: acm-biolabs

ACM Biolabs, founded in 2013 and based in Singapore, is a biotechnology firm that specializes in innovative drug delivery systems and therapeutics. The company is focused on developing polymer-based nanoparticle platforms aimed at enhancing vaccine and therapy delivery for various diseases. Their proprietary technology, known as the ACM Tunable Platform (ATP™), allows for the delivery of multiple drug payloads, including mRNA, proteins, and small molecules. This platform is particularly notable for its thermostability, which enables mRNA storage at 4°C, a significant improvement over traditional lipid-based systems that require ultra-low temperatures. ACM Biolabs has established a clinical pipeline that includes programs targeting infectious diseases, respiratory infections, and oncology. Their recent funding round of $6.8 million in September 2022 underscores their active role in the biotechnology sector and their potential for growth in the nanobiotechnology field.


18. Biotechna S.A.

  • Website: bsbiotechna.com
  • Ownership type: Private
  • Headquarters: Kraków, Lesser Poland Voivodeship, Poland
  • Employee distribution: Poland 100%
  • Founded year: 2019
  • Headcount: 11-50
  • LinkedIn: bs-biotechna

Biotechna S.A., founded in 2019 and based in Kraków, Poland, is a biotechnology firm dedicated to the development of innovative cancer therapies. The company specializes in targeted therapies that leverage nanotechnology and small interfering RNA (siRNA) technology. Their mission is to address significant unmet medical needs in oncology, focusing on creating new synergies in cancer treatment. Biotechna's team consists of highly skilled professionals in nanochemistry, biology, and medicine, who are committed to advancing preclinical and clinical research. They have developed a proprietary nanoparticle platform aimed at delivering nucleic acids and small molecules effectively, which is crucial for enhancing treatment outcomes in various types of cancer. Their research efforts are directed towards silencing traditionally undruggable targets and improving drug delivery systems, showcasing their innovative approach in the biotechnology sector.


19. NeoVac

  • Website: neovac.co.uk
  • Ownership type: Venture Capital
  • Headquarters: Didcot, England, United Kingdom (UK)
  • Employee distribution: United Kingdom (UK) 80%, Zimbabwe 20%
  • Latest funding: Seed, November 2021
  • Founded year: 2021
  • Headcount: 11-50
  • LinkedIn: neovacuk

NeoVac is a biotechnology firm based in Didcot, England, founded in 2021. The company specializes in the development of lipid nanoparticles, particularly for RNA technology and vaccine solutions. Their mission is to create next-generation RNA vaccines and therapeutic interventions that enhance effectiveness and accessibility, addressing critical health challenges. NeoVac's team includes prominent scientists such as Prof. Dan Peer, who has made significant contributions to RNA delivery systems, and Prof. Adrian Hill, known for his work in vaccine development. The company primarily serves pharmaceutical companies and research institutions, aiming to improve vaccine transportability and reduce side effects. With a small but dedicated workforce, NeoVac is positioned as a clinical-stage company with unique intellectual property in lipid nanoparticles, making strides in the biotechnology sector.


20. Zafrens

  • Website: zafrens.com
  • Ownership type: Venture Capital
  • Headquarters: San Diego, California, United States (USA)
  • Employee distribution: United States (USA) 100%
  • Latest funding: Series A, February 2025
  • Founded year: 2022
  • Headcount: 11-50
  • LinkedIn: zafrens

Zafrens, founded in 2022 and based in San Diego, California, is a biotechnology firm that specializes in drug discovery and cellular analysis. The company employs advanced nanofabrication techniques to conduct high-throughput experiments, allowing researchers in the life sciences and pharmaceutical sectors to gain deeper insights into cellular functions and therapeutics. Zafrens aims to democratize access to therapeutics through innovative technology, which is reflected in their development of an experimental platform capable of performing thousands of experiments simultaneously. This platform operates at a scale and resolution that surpasses traditional methods, enabling rapid insights into drug discovery and cellular behavior. Their current focus includes small molecule drug discovery and T cell analysis, with exploratory work in antibody-epitope mapping. Zafrens is positioned to make significant contributions to the biotechnology field, particularly in the area of nanobiotechnology.


21. Ziphius

  • Website: ziphius.org
  • Ownership type: Private
  • Headquarters: Ghent, Flanders, Belgium
  • Employee distribution: Belgium 97%, France 3%
  • Latest funding: Series A, $29.8M, May 2021
  • Founded year: 2019
  • Headcount: 11-50
  • LinkedIn: ziphius-therapeutics

Ziphius is a biotechnology firm based in Ghent, Belgium, founded in 2019. The company is dedicated to developing self-amplifying RNA (saRNA) vaccines and therapeutics, aiming to tackle public health challenges posed by infectious diseases and rare genetic disorders. Ziphius operates within the biotechnology and pharmaceutical sectors, focusing on innovative medical solutions that leverage their proprietary saRNA technology. Their platform allows for rapid and scalable manufacturing of vaccines, which is particularly crucial in responding to emerging health threats. The company has received significant funding, amounting to approximately €29.76 million in a Series A round in May 2021, which supports their ongoing research and development efforts. Ziphius's pipeline includes programs targeting diseases such as Chlamydia trachomatis and cystic fibrosis, showcasing their commitment to advancing healthcare through cutting-edge biotechnological applications.


22. Cellics Therapeutics, Inc.

  • Website: cellics.com
  • Ownership type: Venture Capital
  • Headquarters: San Diego, California, United States (USA)
  • Employee distribution: United States (USA) 100%
  • Latest funding: Series B, $7.0M, February 2022
  • Founded year: 2014
  • Headcount: 11-50
  • LinkedIn: cellics-therapeutics-inc

Cellics Therapeutics, Inc., founded in 2014 and based in San Diego, California, is a biopharmaceutical company that specializes in innovative therapies using Cellular Nanoparticle (CNP™) technology. The company focuses on developing therapeutic nanoparticles designed to restore immune balance and address complex diseases, particularly autoimmune disorders and cytokine storms. Their unique approach involves creating Cellular Nanoparticles that mimic cell membranes, allowing them to neutralize harmful agents such as inflammatory cytokines and autoantibodies. Cellics has established collaborations with industry leaders and academic institutions, including a strategic partnership with CARB-X to develop a novel macrophage nanosponge for treating sepsis. The company has received significant funding, with a Series B round totaling approximately $6.99 million in February 2022, reflecting strong investor confidence in their innovative platform. Cellics aims to provide advanced treatment options for healthcare providers and patients facing serious medical challenges.


23. DIVERSA Technologies


DIVERSA Technologies, founded in 2022 and based in Santiago de Compostela, A Coruña, Spain, is a biotechnology firm focused on advancing drug delivery systems. The company specializes in creating innovative nanoparticle formulations tailored for various therapeutic molecules. Their primary clientele includes researchers and pharmaceutical companies, highlighting their role in the drug development process. DIVERSA aims to address significant challenges in drug delivery by developing solutions that effectively overcome biological barriers, thereby enhancing the efficiency of new therapies. Their product offerings include a range of delivery nanoparticles for small molecules, proteins, peptides, and mRNA, showcasing their commitment to supporting the pharmaceutical industry. As a spin-off from the Santiago de Compostela Health Research Institute, DIVERSA is positioned to leverage academic research and expertise in its operations, further solidifying its relevance in the biotechnology sector.


24. Evozyne

  • Website: evozyne.com
  • Ownership type: Venture Capital
  • Headquarters: Chicago, Illinois, United States (USA)
  • Employee distribution: United States (USA) 100%
  • Latest funding: Series B, $81.0M, September 2023
  • Founded year: 2020
  • Headcount: 51-200
  • LinkedIn: evozyne

Evozyne, founded in 2020 and based in Chicago, Illinois, is a biotechnology firm dedicated to creating novel protein systems aimed at solving critical health challenges. The company specializes in high-performance therapeutic proteins and gene editing technologies, collaborating with pharmaceutical companies to enhance drug development processes. Evozyne's innovative approach leverages generative AI and evolutionary principles to design adaptive proteins, which are essential for addressing complex medical issues. Recently, the company secured $81 million in Series B funding, underscoring its potential and relevance in the biotechnology sector. Their product pipeline includes therapeutics like IgG proteases and a portfolio of CRISPR gene editors, showcasing their commitment to developing life-changing treatments for patients.


25. TeraPore Technologies, Inc.


TeraPore Technologies, Inc., founded in 2013 and based in South San Francisco, California, is a biotechnology company that specializes in nanofiltration solutions tailored for the biopharmaceutical and semiconductor sectors. The company is known for its innovative approach to virus filtration, utilizing its proprietary Intelligent Membrane™ Platform, which employs tunable self-assembled block copolymers. This technology allows for precise control over membrane attributes, enabling effective purification of biologics and advanced therapeutics. TeraPore's flagship product, IsoBlock® VF, is designed to meet the rigorous demands of modern biopharmaceutical manufacturing, ensuring robust viral clearance and consistent performance. The company is actively engaged in research and development, with recent product launches and collaborations that highlight its commitment to addressing complex separation challenges in the industry. TeraPore operates with a small team of dedicated professionals, emphasizing quality and innovation in its manufacturing processes.


26. Invitris

  • Website: invitris.com
  • Ownership type: Venture Capital
  • Headquarters: Munich, Bavaria, Germany
  • Employee distribution: Germany 89%, United Kingdom (UK) 11%
  • Latest funding: Other (Grant), February 2025
  • Founded year: 2022
  • Headcount: 1-10
  • LinkedIn: invitris

Invitris, founded in 2022 and based in Munich, Germany, is a biotechnology company that specializes in the development and manufacturing of synthetic proteins. The company aims to create innovative therapeutic solutions to combat antimicrobial resistance, a pressing global health issue, while also enhancing agricultural productivity. Their technology is centered around a universal platform that utilizes cell-free expression systems, enabling the generation of synthetic proteins with high yields and purity. This platform allows Invitris to produce a range of complex proteins, including bacteriophages, endolysins, and antibodies, which have applications in human health, veterinary medicine, and agriculture. The company is a spin-off from the iGEM Munich Team and has garnered attention for its potential to address significant health challenges. With a small team of 18 employees, Invitris is actively working on developing and validating novel drugs to meet high unmet medical needs, particularly in the fight against antimicrobial resistance.


27. OZ Biosciences

  • Website: ozbiosciences.com
  • Ownership type: Private
  • Headquarters: Marseille, Provence-Alpes-Côte D'Azur, France
  • Employee distribution: France 74%, United States (USA) 26%
  • Latest funding: July 2003
  • Founded year: 2003
  • Headcount: 11-50
  • LinkedIn: oz-biosciences

OZ Biosciences, founded in 2003 and based in Marseille, France, is a biotechnology company that specializes in advanced molecular delivery systems. With a team of 19 employees, the company focuses on providing a range of products that include transfection reagents, viral applications, and lipid nanoparticles. These products are primarily aimed at researchers and pharmaceutical companies within the biotechnology and life sciences sectors. OZ Biosciences has developed several proprietary technologies, such as Magnetofection™ and Lipofection, which enhance the efficiency of gene delivery. Their offerings also include custom services for mRNA synthesis and lipid nanoparticle design, showcasing their commitment to innovation in molecular delivery. The company operates with a significant presence in both France and the United States, reflecting its international reach in the scientific community.


28. Aligned Bio

  • Website: alignedbio.com
  • Ownership type: Venture Capital
  • Headquarters: Jönköping, Jonkoping, Sweden
  • Employee distribution: Sweden 95%, United States (USA) 5%
  • Latest funding: $1.8M, November 2024
  • Founded year: 2019
  • Headcount: 11-50
  • LinkedIn: aligndsystems

Aligned Bio, founded in 2019 and based in Jönköping, Sweden, is a biotechnology firm specializing in advanced nanowire sensor platforms. The company focuses on developing technologies for DNA sequencing and biomarker detection, catering to biomedical companies and research institutions. Their innovative solutions aim to enhance diagnostic sensitivity while lowering costs. Aligned Bio's operations are underpinned by patented production methods, particularly their Aerotaxy technology, which allows for the efficient mass production of nanowires. The company has received notable funding, including a €2.3 million grant from the European Innovation Council, which supports their mission to advance medical diagnostics through their nanowire technology. With a dedicated team of scientists and engineers, Aligned Bio is positioned to make significant contributions to the biomedical market, particularly in the areas of in vitro diagnostics and next-generation sequencing.



Nanobiotechnology Insights: Key Companies


CompanyHeadquarterSizeFoundedOwnership
Precision NanoSystems is now part of CytivaVancouver, British Columbia, Canada51-2002010Corporate
Apurano Pharmaceuticals GmbHWarngau, Bavaria, Germany11-502014Private
nanoComposix | Fortis Life SciencesSan Diego, California, United States (USA)51-2002004Private Equity
Nanovex BiotechnologiesHonduras11-502014Private
Genevant SciencesVancouver, British Columbia, Canada11-502018Private
NanoScoping - NanotechnologyFlorianopolis, Santa Catarina, Brazil11-502014Private
Acuitas TherapeuticsVancouver, British Columbia, Canada51-2002009Private
Magtech BrasilRio De Janeiro, Rio De Janeiro, Brazil1-102017Private
Ceres Nanosciences, Inc.Manassas, Virginia, United States (USA)11-502008Private Equity
ANP Technologies, Inc.United States (USA)11-502002Private
1Globe Health InstituteNorwood, Massachusetts, United States (USA)11-502012Private
MagGenomeChennai, Tamil Nadu, India51-2002014Private
ethernaNiel, Flanders, Belgium51-2002013Venture Capital
Liselo LabsHilton, Kwazulu-Natal, South Africa11-502011Private
AffilogicNantes, Pays De La Loire, France11-502010Private
Peel TherapeuticsSalt Lake City, Utah, United States (USA)11-502015Venture Capital
ACM BiolabsSingapore11-502013Venture Capital
Biotechna S.A.Kraków, Lesser Poland Voivodeship, Poland11-502019Private
NeoVacDidcot, England, United Kingdom (UK)11-502021Venture Capital
ZafrensSan Diego, California, United States (USA)11-502022Venture Capital
ZiphiusGhent, Flanders, Belgium11-502019Private
Cellics Therapeutics, Inc.San Diego, California, United States (USA)11-502014Venture Capital
DIVERSA TechnologiesSantiago De Compostela, A Coruña, Spain1-102022Private
EvozyneChicago, Illinois, United States (USA)51-2002020Venture Capital
TeraPore Technologies, Inc.South San Francisco, California, United States (USA)11-502013Private
InvitrisMunich, Bavaria, Germany1-102022Venture Capital
OZ BiosciencesMarseille, Provence-Alpes-Côte D'Azur, France11-502003Private
Aligned BioJönköping, Jonkoping, Sweden11-502019Venture Capital


Want to Find More Nanobiotechnology Companies?

If you want to find more companies that offer innovative therapies, drug delivery systems, and diagnostic solutions you can do so with Inven. This list was built with Inven and there are hundreds of companies like these globally.

With Inven you'll also get to know the company's:

  • Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
  • Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
  • Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!